This article has Open Peer Review reports available.
Growing PET positive nodule in a patient with histoplasmosis: case report
© Salhab et al; licensee BioMed Central Ltd. 2006
Received: 23 March 2006
Accepted: 04 September 2006
Published: 04 September 2006
Pulmonary histoplasmosis is a mycotic infection that often resembles pulmonary malignancy and continues to complicate the evaluation of pulmonary nodules.
We report a case of an immunocompetent patient who, despite adequate treatment for known histoplasmosis lung infection, presented with radiological and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) findings mimicking primary lung malignancy which eventually required surgical resection.
Histoplasmosis infection may radiologically resemble pulmonary malignancy, often causing a diagnostic dilemma. PET imaging is currently used for and considered accurate in the evaluation of pulmonary nodules. However, overlap in PET standardized uptake value (SUV) between granulomatous and malignant lesions decreases the accuracy of PET as a diagnostic modality. Future advances in PET imaging are needed to improve its accuracy in the evaluation of pulmonary nodules in areas where histoplasmosis is endemic.
Histoplasma capsulatum is a dimorphic fungus that is usually found in the mycelial form in its native state and grows as a yeast at mammalian body temperatures. It was historically first described by Dr. Samuel Darling in 1906, using autopsy material obtained from a patient native to the island of Martinique that died from a wasting febrile illness. The name Histoplasma capsulatum was given to this organism since it was found to be present in histiocytes, and was thought to be an encapsulated plasmodium or protozoan. It has since been well established that H. capsulatum is not a plasmodium, but rather a dimorphic fungus that is usually found in the soil of endemic areas in many parts of the world.
The clinical and radiological presentation of pulmonary histoplasmosis is variable. Often, the infection may mimic lung neoplasm and may require thoracoscopy or open lung biopsy to establish a definitive diagnosis. F-18 FDG PET, increasingly used in the assessment of pulmonary nodules, is reevaluated as an accurate imaging modality in the diagnosis of pulmonary histoplasmosis in this case presentation.
A 64-year-old fisherman presented to his primary care physician with fever, chills, and generalized malaise of three days duration. The patient had recently returned from a 2 week vacation to Guatemala and Belize. His medical history included prostate cancer and hyperlipidemia. He reported a distant history of tobacco-smoking. The patient appeared well and was in no acute distress. His physical examination was unremarkable except for an elevated temperature of 102 degrees Fahrenheit. Blood tests including complete blood count and differential, thick and thin smears for malaria, and dengue serology were normal. He was treated with oral clarithromycin 500 mg twice a day for one week. A second course of clarithromycin for a period of 14 days was initiated two weeks later for persistent fever and malaise, in addition to new complaints of severe bone pain and weight loss. After six weeks, the fever subsided and his constitutional symptoms improved.
He underwent a right thoracoscopy with wedge resection of the right upper lobe peripheral pulmonary nodule. Histopathology revealed multiple granulomata with extensive necrosis. Methenamine silver stains demonstrated yeast consistent with histoplasma within the necrotic foci. The patient was started on oral itraconazole capsules, 200 mg once a day.
The patient underwent a left lower lobectomy. Pathology revealed necrotizing granulomata resembling that seen in the prior biopsy; visible fungal elements consistent with histoplasmosis were visible upon silver staining. Interestingly, operative fungal cultures were negative, suggesting the growth in the lesion was likely from host immune response, not from progression of infection. The formulation of the patient's itraconazole was changed to an oral solution, 200 mg once a day for an additional three months. A follow up CT scan at one year duration has not shown any recurrence of disease.
H. capsulatum is endemic to many parts of the world, in particular Latin America and the areas of the Midwestern and Southcentral United States [1, 2]. It is found to prefer moist soil as a habitat, mainly that contaminated by droppings of birds and bats [3, 4]. The pathogenesis of histoplasmosis infection starts with the disruption of the soil. As a result, the hyphae and conidia of H. capsulatum become aerosolized, inhaled and deposited into the lung. There, the fungus is engulfed by macrophages and other phagosomes, but eludes elimination by converting to the yeast form. The yeast cells then reside and multiply within the phagolysosomal vesicles, possibly through a mechanism that elevates intraphagosomal pH [5, 6]. In the absence of cell mediated immunity (CMI), the yeasts continue to multiply and disseminate to involve organs of the reticulo-endothelial system. Once CMI develops, in the immunocompetent adult, the formation of a granuloma begins and the intracellular yeasts are finally destroyed.
The clinical presentation of acute histoplasmosis usually depends on the size of the inoculum and the immune response of the host. The vast majority of infections are asymptomatic or present as an influenza-like illness, with cough, fever, and headache. Chest radiographic findings typically demonstrate small areas of infiltrate or mediastinal lymphadenopathy. With time, a granulomatous reaction occurs with areas of caseating necrosis leading to the appearance of a round mass of scar tissue that may or may not be calcified, known as a histoplasmoma.
In patients with known underlying lung disease, such as emphysema or COPD, a chronic form of pulmonary histoplasmosis may occur. This infection usually starts by the colonization of diseased lung tissue in the upper zones, and progresses gradually, leading to cavity formation and scarring. Symptoms are characterized by a productive cough, fever, hemoptysis, weight loss, and occasional night sweats along with lung cavitations that may be seen on chest radiographs, often mimicking tuberculosis.
Patients with inadequate CMI, such as those receiving immunosuppressive therapy or those infected with the Human Immunodeficiency Virus (HIV), may develop progressive disseminated histoplasmosis, an often rapidly progressive and fatal illness that presents with fever, anemia, leukopenia, hepatosplenomegaly, central nervous system involvement, and cardiac manifestations.
Several laboratory tests are useful in the diagnosis of infections caused by H. capsulatum. Culture samples of the organism remain the gold standard for diagnosis. The samples are usually recovered from bone marrow, liver, sputum, and bronchoalveolar lavage. Histopathologic visualization using special stains such as Giemsa or Methenamine Silver stains also aids in the diagnosis and yields very rapid results. Complement fixation is another test used for the diagnosis of H. capsulatum, detecting both mycelial and yeast antigens.
Most patients with the acute form of histoplasmosis do not require antimicrobial therapy, as they remain asymptomatic or improve spontaneously. Patients presenting with the chronic form of histoplasmosis are usually treated with itraconazole for 6–12 months as a first line of treatment. Patients presenting with progressive disseminated histoplasmosis usually require induction therapy with intravenous amphotericin B, although it has been shown that some patients may respond to itraconazole as a first line therapy . Once stabilized, patients may be switched from amphotericin B to itraconazole. Patients with HIV who present with progressive disseminated histoplasmosis require life-long maintenance therapy.
Surgical intervention is occasionally required in patients with histoplasmosis. The finding of a histoplasmoma presenting as a lung nodule or mass on a chest X-ray or CT scan often raises concern for malignancy, which may require thoracoscopic or open lung biopsy to establish a definitive diagnosis.
Standard Uptake Values of FDG-PET in Histoplasmosis
No. of Patients
0.42 and 0.82
1.92 and 3.38
Caseating granuloma with Histoplasma
Necrotizing granuloma with histoplasmosis
4.0 and 4.5
This case illustrates the difficulty in differentiating active histoplasmosis infection from malignancy. Despite known pulmonary histoplasmosis infection, there remained significant concern that the left lower lobe lesion of the patient presented herein was a concurrent malignancy, especially when the lesion grew in spite of adequate antifungal therapy. An increase in FDG uptake, with an SUV of 3.8, further raised this concern. A second pulmonary resection was ultimately required to definitively rule out malignancy in this otherwise healthy, immunocompetent individual.
In conclusion, though a self-limited disease in most patients, H. capsulatum infection continues to complicate the evaluation of pulmonary nodules and often leads to surgical resection. PET imaging is likely not useful in determining the correct clinical approach in this disease, as false positives are quite common in granulomatous lesions. Perhaps future advances in PET imaging or the use of delayed scanning may increase the accuracy of this modality for cancer detection in areas where histoplasmosis is endemic.
- Edwards LD, Acquaviva FA, Livesay VT, Cross FW, Palmer CE: An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. 1969, 1-132. SupplGoogle Scholar
- Cano MV, Hajjeh RA: The epidemiology of histoplasmosis: a review. Semin Respir Infect. 2001, 16: 109-18.View ArticlePubMedGoogle Scholar
- Goodwin RA, Loyd JE, Des Prez RM: Histoplasmosis in normal hosts. Medicine (Baltimore). 1981, 60: 231-66.View ArticleGoogle Scholar
- Emmons CW: Association of bats with histoplasmosis. Public Health Rep. 1958, 73: 590-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Eissenberg LG, Goldman WE, Schlesinger PH: Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med. 1993, 177: 1605-11. 10.1084/jem.177.6.1605.View ArticlePubMedGoogle Scholar
- Newman SL, Gootee L, Morris R, Bullock WE: Digestion of Histoplasma capsulatum yeasts by human macrophages. J Immunol. 1992, 149: 574-80.PubMedGoogle Scholar
- Dismukes WE, Bradsher RW, Cloud GC, Kauffman CA, Chapman SW, George RB, Stevens DA, Girard WM, Saag MS, Bowles-Patton C: Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med. 1992, 93: 489-97. 10.1016/0002-9343(92)90575-V.View ArticlePubMedGoogle Scholar
- Patz EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993, 188: 487-90.View ArticlePubMedGoogle Scholar
- Lewis PJ, Salama A: Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994, 35: 1647-9.PubMedGoogle Scholar
- Yang CM, Hsu CH, Lee CM, Wang FC: Intense uptake of [F-18]-fluoro-2 deoxy-D-glucose in active pulmonary tuberculosis. Ann Nucl Med. 2003, 17: 407-10.View ArticlePubMedGoogle Scholar
- Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP: Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 1993, 104: 997-1002.View ArticlePubMedGoogle Scholar
- Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, Phalen JJ, Sunderland JJ, Frick MP: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1992, 184: 441-4.View ArticlePubMedGoogle Scholar
- Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998, 16: 1075-84.PubMedGoogle Scholar
- Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, Peterson MW, Gross T, McLennan G, Kern JA: FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002, 36: 297-301. 10.1016/S0169-5002(02)00023-5.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.